Hybio Pharmaceutical Co., Ltd.
SHZ: 300199.SZ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Shaogui Zeng
- Employees
- 895
- Headquarters
- Shenzhen, China
- IPO year
- 2011
- Market cap
- CN¥18.1B
- Website
- https://www.hybio.com.cn
Loading 300199…
Loading profile data…Frequently asked questions about 300199
What does Hybio Pharmaceutical Co., Ltd. (300199.SZ) do?
Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cet...
Where does 300199.SZ trade?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) trades on the Shenzhen Stock Exchange.
What sector is 300199.SZ in?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Hybio Pharmaceutical Co., Ltd.?
Shaogui Zeng is the chief executive officer of Hybio Pharmaceutical Co., Ltd. (300199.SZ).
Where is Hybio Pharmaceutical Co., Ltd. headquartered?
Hybio Pharmaceutical Co., Ltd. is headquartered in China.
Does 300199.SZ pay a dividend?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 300199.SZ go public?
Hybio Pharmaceutical Co., Ltd. (300199.SZ) completed its initial public offering in 2011.